Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Feb 25;141(8):641-651.
doi: 10.1161/CIRCULATIONAHA.119.044352. Epub 2019 Nov 17.

Results of the FUEL Trial

David J Goldberg  1 , Victor Zak  2 , Bryan H Goldstein  3 , Kurt R Schumacher  4 , Jonathan Rhodes  5 , Daniel J Penny  6 , Christopher J Petit  7 , Salil Ginde  8 , Shaji C Menon  9 , Seong-Ho Kim  10 , Gi Beom Kim  11 , Todd T Nowlen  12 , Michael V DiMaria  13 , Benjamin P Frischhertz  14 , Jonathan B Wagner  15 , Kimberly E McHugh  16 , Brian W McCrindle  17 , Amanda J Shillingford  18 , Arash A Sabati  19 , Anji T Yetman  20 , Anitha S John  21 , Marc E Richmond  22 , Matthew D Files  23 , R Mark Payne  24 , Andrew S Mackie  25 , Christopher K Davis  26 , Shabana Shahanavaz  27 , Kevin D Hill  28 , Ruchira Garg  29 , Jeffrey P Jacobs  30 , Michelle S Hamstra  3 , Stacy Woyciechowski  1 , Kathleen A Rathge  3 , Michael G McBride  1 , Peter C Frommelt  8 , Mark W Russell  4 , Elaine M Urbina  3 , James L Yeager  31 , Victoria L Pemberton  32 , Mario P Stylianou  32 , Gail D Pearson  32 , Stephen M Paridon  1 ; Pediatric Heart Network Investigators
Affiliations
Clinical Trial

Results of the FUEL Trial

David J Goldberg et al. Circulation. .

Erratum in

  • Correction to: Results of the FUEL Trial.
    [No authors listed] [No authors listed] Circulation. 2020 Jul 14;142(2):e31. doi: 10.1161/CIR.0000000000000882. Epub 2020 Jul 13. Circulation. 2020. PMID: 32658610 No abstract available.

Abstract

Background: The Fontan operation creates a total cavopulmonary connection, a circulation in which the importance of pulmonary vascular resistance is magnified. Over time, this circulation leads to deterioration of cardiovascular efficiency associated with a decline in exercise performance. Rigorous clinical trials aimed at improving physiology and guiding pharmacotherapy are lacking.

Methods: The FUEL trial (Fontan Udenafil Exercise Longitudinal) was a phase III clinical trial conducted at 30 centers. Participants were randomly assigned udenafil, 87.5 mg twice daily, or placebo in a 1:1 ratio. The primary outcome was the between-group difference in change in oxygen consumption at peak exercise. Secondary outcomes included between-group differences in changes in submaximal exercise at the ventilatory anaerobic threshold, the myocardial performance index, the natural log of the reactive hyperemia index, and serum brain-type natriuretic peptide.

Results: Between 2017 and 2019, 30 clinical sites in North America and the Republic of Korea randomly assigned 400 participants with Fontan physiology. The mean age at randomization was 15.5±2 years; 60% of participants were male, and 81% were white. All 400 participants were included in the primary analysis with imputation of the 26-week end point for 21 participants with missing data (11 randomly assigned to udenafil and 10 to placebo). Among randomly assigned participants, peak oxygen consumption increased by 44±245 mL/min (2.8%) in the udenafil group and declined by 3.7±228 mL/min (-0.2%) in the placebo group (P=0.071). Analysis at ventilatory anaerobic threshold demonstrated improvements in the udenafil group versus the placebo group in oxygen consumption (+33±185 [3.2%] versus -9±193 [-0.9%] mL/min, P=0.012), ventilatory equivalents of carbon dioxide (-0.8 versus -0.06, P=0.014), and work rate (+3.8 versus +0.34 W, P=0.021). There was no difference in change of myocardial performance index, the natural log of the reactive hyperemia index, or serum brain-type natriuretic peptide level.

Conclusions: In the FUEL trial, treatment with udenafil (87.5 mg twice daily) was not associated with an improvement in oxygen consumption at peak exercise but was associated with improvements in multiple measures of exercise performance at the ventilatory anaerobic threshold.

Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02741115.

Keywords: Fontan procedure; exercise test; heart defects, congenital; phosphodiesterase 5 inhibitor.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Randomization and Treatment of FUEL Participants. Peak VO2 denotes oxygen consumption at peak exercise. RER denotes respiratory exchange ratio.
Figure 2.
Figure 2.
Oxygen consumption at peak exercise. Panel A demonstrates the difference in the change in mean peak VO2 from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in peak VO2 by the reference percentage or greater (x axis).
Figure 2.
Figure 2.
Oxygen consumption at peak exercise. Panel A demonstrates the difference in the change in mean peak VO2 from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in peak VO2 by the reference percentage or greater (x axis).
Figure 3.
Figure 3.
Oxygen consumption at the ventilatory anaerobic threshold. Panel A demonstrates the difference in the change in mean VO2 at VAT from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in VO2 at VAT by the reference percentage or greater (x axis).
Figure 3.
Figure 3.
Oxygen consumption at the ventilatory anaerobic threshold. Panel A demonstrates the difference in the change in mean VO2 at VAT from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in VO2 at VAT by the reference percentage or greater (x axis).
Figure 4.
Figure 4.
Work at the ventilatory anaerobic threshold. Panel A demonstrates the difference in the change in mean work rate at VAT from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in work rate by the reference percentage or greater (x axis).
Figure 4.
Figure 4.
Work at the ventilatory anaerobic threshold. Panel A demonstrates the difference in the change in mean work rate at VAT from Baseline to Week 26 along with the standard deviation for each treatment arm. Panel B demonstrates the percentage of participants (y axis) who demonstrated improvement in work rate by the reference percentage or greater (x axis).
See this image and copyright information in PMC

Comment in

References

    1. Fontan F and Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26:240–8. - PMC - PubMed
    1. Kreutzer G, Galindez E, Bono H, De Palma C and Laura JP. An operation for the correction of tricuspid atresia. The Journal of thoracic and cardiovascular surgery. 1973;66:613–21. - PubMed
    1. Gewillig M and Goldberg DJ. Failure of the fontan circulation. Heart Fail Clin. 2014;10:105–16. - PubMed
    1. Egbe AC, Connolly HM, Miranda WR, Ammash NM, Hagler DJ, Veldtman GR and Borlaug BA. Hemodynamics of Fontan Failure: The Role of Pulmonary Vascular Disease. Circ Heart Fail. 2017;10(12):1–8. - PMC - PubMed
    1. Gewillig M, Brown SC, Eyskens B, Heying R, Ganame J, Budts W, La Gerche A and Gorenflo M. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 2010;10:428–33. - PubMed

Publication types

MeSH terms

Associated data